<div id="readability-page-1"><p><span>AbbVie (NYSE:ABBV - Get Free Report)</span> had its target price upped by JPMorgan Chase &amp; Co.  from $250.00 to $260.00 in a research note issued on Monday,Benzinga reports. The firm currently has an &#34;overweight&#34; rating on the stock. JPMorgan Chase &amp; Co.'s target price points to a potential upside of 20.05% from the stock's current price.</p><ul><li>ABBV Stock: $250 May Be the New Floor After Big Q3 Earnings Beat</li></ul><p>A number of other equities analysts also recently commented on the stock. Evercore ISI boosted their target price on shares of AbbVie from $207.00 to $222.00 and gave the stock an &#34;outperform&#34; rating in a research note on Monday, September 22nd. Wall Street Zen raised shares of AbbVie from a &#34;hold&#34; rating to a &#34;buy&#34; rating in a research report on Saturday, October 25th. Piper Sandler upped their target price on shares of AbbVie from $231.00 to $284.00 and gave the company an &#34;overweight&#34; rating in a report on Friday, October 10th. Erste Group Bank cut shares of AbbVie from a &#34;buy&#34; rating to a &#34;hold&#34; rating in a report on Tuesday, October 14th. Finally, Wells Fargo &amp; Company upped their target price on shares of AbbVie from $240.00 to $260.00 and gave the stock an &#34;overweight&#34; rating in a research report on Friday, September 12th. Two investment analysts have rated the stock with a Strong Buy rating, sixteen have issued  a Buy rating and nine have issued  a Hold rating to the company. Based on data from MarketBeat.com, the company  has an average rating of &#34;Moderate Buy&#34; and an average target price of $236.35.</p><p><b>View Our Latest Research Report on AbbVie</b></p><h2>AbbVie Stock Performance</h2><ul><li>Why AbbVie and Johnson &amp; Johnson Could Outperform Pfizer</li></ul><p>NYSE:ABBV opened at $216.57 on Monday. The company has a quick ratio of 0.61, a current ratio of 0.74 and a debt-to-equity ratio of 44.14. The company has a fifty day simple moving average of $222.42 and a two-hundred day simple moving average of $201.15. The company has a market cap of $382.59 billion, a price-to-earnings ratio of 103.13, a price-to-earnings-growth ratio of 1.42 and a beta of 0.51. AbbVie has a 52 week low of $163.81 and a 52 week high of $244.81. </p><p>AbbVie (NYSE:ABBV - Get Free Report) last issued its earnings results on Friday, October 31st. The company reported $1.86 EPS for the quarter, topping analysts' consensus estimates of $1.77 by $0.09. The firm had revenue of $15.78 billion during the quarter, compared to the consensus estimate of $15.58 billion. AbbVie had a net margin of 6.45% and a return on equity of 699.66%. The company's revenue was up 9.1% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $3.00 earnings per share.  AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS. As a group, equities analysts anticipate that  AbbVie will post 12.31 earnings per share for the current fiscal year. </p><h2>Insiders Place Their Bets</h2><ul><li>3 Exceptional Stocks to Build Long-Term Wealth</li></ul><p>In related news, EVP Azita Saleki-Gerhardt sold 42,370 shares of the stock in a transaction dated Tuesday, August 12th. The shares were sold at an average price of $198.42, for a total transaction of $8,407,055.40. Following the sale, the executive vice president owned 177,292 shares in the company, valued at $35,178,278.64. This represents a 19.29% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities &amp; Exchange Commission, which is available through this hyperlink. Also, EVP Nicholas Donoghoe sold 13,295 shares of the firm's stock in a transaction on Tuesday, August 5th. The shares were sold at an average price of $198.51, for a total value of $2,639,190.45. Following the completion of the sale, the executive vice president owned 58,247 shares in the company, valued at $11,562,611.97. The trade was a 18.58% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. 0.25% of the stock is currently owned by corporate insiders. </p><h2>Institutional Inflows and Outflows</h2><p>A number of large investors have recently modified their holdings of the business. Conning Inc. grew its position in  AbbVie by 7.1% during the 2nd quarter. Conning Inc. now owns 191,023 shares of the company's stock worth $35,458,000 after acquiring an additional 12,690 shares during the last quarter.  Dohj LLC boosted its position in shares of  AbbVie by 41.8% during the 2nd quarter. Dohj LLC now owns 4,529 shares of the company's stock valued at $802,000 after purchasing an additional 1,335 shares in the last quarter.  First Hawaiian Bank raised its stake in  AbbVie by 0.8% during the 2nd quarter. First Hawaiian Bank now owns 7,556 shares of the company's stock worth $1,403,000 after buying an additional 60 shares during the period.  Narus Financial Partners LLC raised its stake in  AbbVie by 25.3% during the 1st quarter. Narus Financial Partners LLC now owns 1,988 shares of the company's stock worth $417,000 after buying an additional 401 shares during the period.  Finally, BankPlus Trust Department raised its stake in  AbbVie by 3.3% during the 2nd quarter. BankPlus Trust Department now owns 27,113 shares of the company's stock worth $5,033,000 after buying an additional 855 shares during the period. 70.23% of the stock is currently owned by institutional investors and hedge funds. </p><h2>AbbVie Company Profile</h2> (Get Free Report)<p>AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.</p><h2>Recommended Stories</h2><ul><li>Five stocks we like better than AbbVie</li><li>When to Sell a Stock for Profit or Loss</li><li>Boeing Closes in on Airbus With Best Delivery Quarter Since 2018</li><li>How to Buy Gold Stock and Invest in Gold</li><li>Put It on My Card: Why Luxury Brands and Payments Firms Pair Well</li><li>The Significance of a Trillion-Dollar Market Cap Goes Beyond a Number</li><li>3 Safe and Steady Stocks for Any Market</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUFCQlY?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="330" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUFCQlY"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in AbbVie Right Now?</h2><p>Before you consider AbbVie, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and AbbVie wasn't on the list.</p><p>While AbbVie currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

ABBV

<p>JPMorgan Chase & Co. has raised its target price for AbbVie (NYSE:ABBV) from $250.00 to $260.00, maintaining an "overweight" rating. This new target suggests a potential upside of 20.05% from the current stock price. Other analysts have also adjusted their ratings and target prices for AbbVie, with an average rating of "Moderate Buy" and a target price of $236.35. AbbVie recently reported strong Q3 earnings, exceeding estimates with $1.86 EPS and $15.78 billion in revenue, marking a 9.1% year-over-year increase.</p>

AbbVie (NYSE:ABBV) Given New $260.00 Price Target at JPMorgan Chase & Co.